Luminopia develops digital therapeutics for treating amblyopia (lazy eye) in children using modified TV shows and movies.

Luminopia

Luminopia is pioneering a new class of treatments for significant neuro-visual disorders. Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product to treat amblyopia, the leading cause of vision loss among children. For more information, visit luminopia.com. 

Please see Luminopia Directions For Use for more information: luminopia.com/dfu

MassChallenge

Bantam Group

Sesame Ventures

The Vertical Group

Shangbay Capital

Sony Innovation Fund

SSI Strategy

NXT Ventures

U.S. Venture Partners

Broadfin Advisors

We’re thrilled to announce the closing of our oversubscribed Series A financing round, led by USVP, with participation from new investor Broadfin Advisors, and support from existing investors ShangBay Capital and Vertical Group. We are bringing in $16m in new capital, which will allow us to expand to a national launch of our lead product, an FDA-approved therapeutic for amblyopia, the leading cause of vision loss in kids, which allows patients to watch TV as treatment instead of wearing an eye-patch. This round also allows us to advance our broader mission of pioneering a new class of treatments for serious neuro-visual disorders.

We are excited to be partnering with the team at USVP, given their extensive track record building innovative companies at the intersection of healthcare and technology. We are grateful to our investors for their support and belief in our vision, and we can’t wait to bring the first new amblyopia treatment in decades to patients and families across the country.

#healthcare #technology #amblyopia #healthtech #digitaltherapeutics 

https://lnkd.in/eNBvxJVg

🎥 Announcing Our New YouTube Channel! 🎥

We're excited to launch the Luminopia YouTube channel, a valuable resource for both parents and physicians. Our channel features informative videos on amblyopia, Luminopia, and expert testimonials from clinicians. Subscribe now to stay updated with the latest information designed to support our community.

Watch, learn, and share: https://lnkd.in/gAbr3txG 

#Luminopia #Ophthalmology #Optometry #AmblyopiaAwarenessMonth

Highmark's New Technology Advisory Committee (NTAC) sets a gold standard for assessing new tech before making it available to members. Today we're proud to announce that Luminopia has been approved by Highmark for coverage for children with amblyopia. We appreciate Highmark's thoughtful and evidence-based approach, and we are committed to continually improving access to our product for patients in need. 

You can read the press release here: https://lnkd.in/gSPfxjFs  

#AmblyopiaAwarenessMonth #HealthTech #PrescriptionDigitalTherapies #PDTs #Ophthalmology #Optometry #luminopia

🌟 August is Amblyopia Awareness Month 🌟
At Luminopia, we’re committed to improving the lives of young children with amblyopia. Amblyopia, often referred to as "lazy eye," is the leading cause of vision loss in children. For many generations, eye patches and atropine drops were the only available treatments and many patients still have amblyopia after trying these therapies. Luminopia was developed out of the urgent need for treatments that are engaging and effective for patients.
 
We extend our gratitude to the dedicated pediatric ophthalmologists, optometrists, orthoptists, and their teams who work tirelessly to diagnose and treat amblyopia.

Join us this month in raising awareness about amblyopia and advocating for early treatment. You can learn more about this condition at  https://lnkd.in/gM--p_56 

#AmblyopiaAwarenessMonth #HealthTech #PrescriptionDigitalTherapies #PDTs #Ophthalmology #Optometry #luminopia

🌟 We’re Hiring! 🌟 Key Account Manager (Florida or New England)

Are you action-oriented, entrepreneurial, and passionate about serving pediatric patients? If so, we have an exciting opportunity for you! Do you thrive in a fast-paced environment where curiosity and innovation are valued? If so, lets talk!

👉🏾 About Us:
At Luminopia, we are focused on advancing care in pediatric ophthalmology through digital therapeutics. We are pioneering a new class of treatments for neuro-visual disorders starting with our first product in pediatric amblyopia. We are passionate about helping kids have a clearer future!

🔎 Who We're Looking For:
We are seeking exceptional sales professionals who are driven by a sense of purpose and are eager to help kids and pave a new path for healthcare in the digital therapeutics space.

Our ideal candidate is:

🚀 **Self-Motivated**: You have an innate drive to achieve and surpass sales targets. Your determination and proactive attitude fuel your success.

🌱 **Entrepreneurial Spirit**: You're not afraid to take the initiative and explore new opportunities. You excel at building and nurturing client relationships.

💡 **Curious & Adaptable**: You possess a thirst for knowledge and enjoy staying up-to-date with the latest advancements .You adapt quickly to evolving market trends.

💗 **Passionate**: Your passion for helping others through healthcare, especially children, shines through in your work.

📢 How to Apply:
If this is you, we want to connect! Send us a direct message or email at hiring@luminopia.com with your updated resume.

Come join the Luminopia Team!

#Hiring #Salesforce #PediatricOphthalmology #DigitalTherapeutics #HealthcareInnovation #JoinOurTeam #SalesProfessionals 
#CareerOpportunity #MakingADifference #Healthcare #Innovation 
#EntrepreneurialSpirit

Derek Sprunger, MD, FAAO, Professor, Indiana University School of Medicine, presented real-world data from the PUPiL Registry at the European and International Strabismological Association conference this past weekend.

The PUPiL Registry collects real world data from patients prescribed Luminopia. In this analysis, Registry patients with similar characteristics as patients enrolled in the phase 3 clinical trial saw a 1.7-line improvement in BCVA and maintained a median adherence of 83%. No safety events were reported among registry participants. These promising results continue to support Luminopia as an engaging and effective treatment option for children with amblyopia.

Luminopia is committed to being a science-first company and will continue to support the PUPiL Registry to collect and analyze real-world patient data. Please read the full press release linked below!

https://lnkd.in/gkAXWSFf

#luminopia #amblyopia #lazyeye #ophthalmology #healthtech #digitaltherapy #digitaltherapeutics

🎉Happy World Orthoptic Day! 👀

Today, we honor and celebrate the invaluable contributions of Orthoptists to the field of pediatric ophthalmology. 🌟

Orthoptists are the unsung heroes behind countless success stories in improving children's vision. They are responsible for conducting comprehensive eye exams and oversee treatment plans for conditions like amblyopia. Their expertise and dedication make a profound impact on the young patients they see every day. 👓

We can’t wait to connect with many orthoptists at AACO later this year! 💙

#amblyopia #lazyeye #ophthalmology #optometry #healthtech #orthoptists #worldorthopticday

🎉 Our new website is live! 🎊

We’ve completely overhauled luminopia.com to become the best online resource for physicians and parents who are looking for more information about Luminopia and amblyopia. We’ve transformed the site to embody our company’s values and commitment to serving as many appropriate patients as possible. Explore it now! 👀 💻 

#ophthalmology #optometry #healthtech #amblyopia #lazyeye

We’re looking forward to Luminopia registry data being presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting for the first time.  

Dr Brenda Bohnsack of Ann & Robert H. Lurie Children's Hospital of Chicago and Dr Fatema Ghasia of Cleveland Clinic will each share data from the PUPiL registry.

#lazyeye #amblyopia #ARVO2024 #ophthalmology #optometry #healthtech

📣 Follow us on other social channels! 🎉 We’ve revamped our social media channels across Instagram, Facebook, and X (Twitter). We’ll use these platforms to share more updates about our company, advancements in our technology, and the meaningful impact we’re making on patients and their families. Give us a follow at: 

🔹 Facebook: facebook.com/luminopia
🔹 Instagram: @luminopia 
🔹 X (Twitter): @luminopia

news impact assignment basic	general
public peers	general	Aug 26, 2024 4:50 AM	99738c16
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 26, 2024 4:50 AM	de3379db
translate crunchbase fundingrounds	general
peers	general	Aug 26, 2024 4:50 AM	60110f2b
news basic	general	Aug 26, 2024 4:50 AM	26aaaedc
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

LUMI

COM:LUMINOPIA

Luminopia